| ID | 1129 |
| Name of the vaccine | Menomune |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Polysaccharide |
| Nucleic acid content | DNA |
| Age | 2 years and older |
| Description of the vaccine | Meningococcal polysaccharide vaccine, groups A, C, Y and W-135. |
| Name of the manufacturer | Sanofi Pasteur Inc. |
| Name of the manufacturing country | United States |
| Year of manufacture | 1981 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | For serogroup A : 87%
For serogroup C : 12% in children 6 to 23 months and 55% in children 24 to 36 months. |
| Vaccine formulation | Lyophilized vaccine, diluent used for reconstitution. |
| Dosage | Single dose of 0.5 mL.
Subjects who remain at risk should be revaccinated using a single dose every 3 years. |
| Mechanism of action | Production of bactericidal antibodies specific to the capsular polysaccharides of serogroups A, C, Y and W-135. |
| Route of administration | Subcutaneous |
| Indications | Invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Injection site pain, irritability, diarrhoea, headache, fatigue, malaise, arthralgia. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/83562/download |
| Other name | NA |
| Additional Links | NA
|